The patient developed this cutaneous adverse reaction 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A). Epidermal growth factor receptor (EGFR) inhibitor
B.) Tumor necrosis factor (TNF)-alpha inhibitor
C.) Smoothened inhibitor
D.) BRAF inhibitor
E.) Programmed cell death (PD)-1 inhibitor
To find out the correct answer and read the explanation, click here.